BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21339094)

  • 21. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy.
    Schrader KA; Hurlburt J; Kalloger SE; Hansford S; Young S; Huntsman DG; Gilks CB; McAlpine JN
    Obstet Gynecol; 2012 Aug; 120(2 Pt 1):235-40. PubMed ID: 22776961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early detection of breast and ovarian cancer in families with BRCA mutations.
    Vasen HF; Tesfay E; Boonstra H; Mourits MJ; Rutgers E; Verheyen R; Oosterwijk J; Beex L
    Eur J Cancer; 2005 Mar; 41(4):549-54. PubMed ID: 15737559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective.
    Woodward ER; Sleightholme HV; Considine AM; Williamson S; McHugo JM; Cruger DG
    BJOG; 2007 Dec; 114(12):1500-9. PubMed ID: 17903229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.
    Lu KH; Garber JE; Cramer DW; Welch WR; Niloff J; Schrag D; Berkowitz RS; Muto MG
    J Clin Oncol; 2000 Jul; 18(14):2728-32. PubMed ID: 10894872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer screening and risk-reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers.
    MacDonald DJ; Sarna L; Uman GC; Grant M; Weitzel JN
    Oncol Nurs Forum; 2006 Nov; 33(2):E27-35. PubMed ID: 16518435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CA125 screening after risk-reducing salpingo-oophorectomy: are the titers too high, or is it all just too much?
    Bradford LS; Schorge JO
    Menopause; 2011 Feb; 18(2):123-4. PubMed ID: 21191312
    [No Abstract]   [Full Text] [Related]  

  • 29. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
    Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery.
    Rabban JT; Garg K; Crawford B; Chen LM; Zaloudek CJ
    Am J Surg Pathol; 2014 Jun; 38(6):729-42. PubMed ID: 24820399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genital Cancers in Women: Ovarian Cancer.
    Kuznia AL; Roett MA
    FP Essent; 2015 Nov; 438():24-30. PubMed ID: 26569048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
    Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
    JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
    Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
    J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hereditary ovarian cancer--assessing risk and prevention strategies.
    Pavelka JC; Li AJ; Karlan BY
    Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
    Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
    Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
    [No Abstract]   [Full Text] [Related]  

  • 37. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
    Fishman DA; Cohen L; Blank SV; Shulman L; Singh D; Bozorgi K; Tamura R; Timor-Tritsch I; Schwartz PE
    Am J Obstet Gynecol; 2005 Apr; 192(4):1214-21; discussion 1221-2. PubMed ID: 15846205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Familial ovarian cancer screening.
    Rosenthal A; Jacobs I
    Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):321-38. PubMed ID: 16364691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level?
    van Altena AM; Holtsema H; Hendriks JC; Massuger LF; de Hullu JA
    Menopause; 2011 Feb; 18(2):133-7. PubMed ID: 20861755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - a case report of primary papillary serous carcinoma presenting as sigmoid cancer.
    Chand M; Moore PJ; Clarke AD; Nash GF; Hickisk T
    World J Surg Oncol; 2007 Sep; 5():102. PubMed ID: 17850658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.